Healthcare

Compounding Pharmacy Market Size To Cross USD 28.19 Bn By 2032

The global compounding pharmacy market size accounted for US$ 14.92 Bn in 2022 and is projected to reach around USD 28.19 Bn by 2032, growing at a CAGR of 6.57% from 2023 to 2032.

Compounding Pharmacy Market Size 2023 To 2032

Key Takeaways:

  • North America is expected to dominate the market during the forecast period.
  • By therapeutic area, the pain management segment is expected to dominate the market over the forecast period.
  • By route of administration, the oral segment is expected to hold the largest revenue share over the forecast period.
  • By distribution channel, the hospital pharmacy segment is expected to dominate the market over the forecast period.

Report Summary

The global compounding pharmacy market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the compounding pharmacy market across the globe.

A comprehensive estimate on the compounding pharmacy market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of compounding pharmacy during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3185

Compounding Pharmacy Market Report Scope 

Report Coverage Details
Market Size in 2023 USD 15.9 Billion
Market Size by 2032 USD 28.19 Billion
Growth Rate from 2023 to 2032 CAGR of 6.57%
Largest Market North America
Base Year 2022
Forecast Period 2023 To 2032
Segments Covered By Therapeutic Area, By Route of Administration, By Application, By Compounding Type, By Sterility, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized compounding pharmacy market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Grow Lights Market Size To Cross USD 24.44 Bn By 2032

Compounding Pharmacy Market Players

The report includes the profiles of key compounding pharmacy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Fresenius Kabi
  • Fagron NV
  • B. Braun Medical Inc.
  • Rx3 Compounding Pharmacy
  • Clinigen Group PLC
  • Dougherty’s Pharmacy, Inc.
  • Lorraine’s Pharmacy
  • Wedgewood Pharmacy
  • Institutional Pharmacy Solutions
  • Mcguff compounding pharmacy services

Market Segmentation

By Therapeutic Area

  • Pain Management
  • Hormone Replacement
  • Dermal Disorders
  • Nutritional Supplements
  • Others

By Route of Administration

  • Oral
  • Topical
  • Parenteral
  • Others

By Application

  • Pediatric
  • Geriatric
  • Adult
  • Veterinary

By Compounding Type

  • Pharmaceutical Dosage Alteration (PDA)
  • Pharmaceutical Ingredient Alteration (PIA)
  • Currently Unavailable Pharmaceutical Manufacturing (CUPM)
  • Others

By Sterility

  • Sterile
  • Non-sterile

By Distribution Channel

  • Compounding Pharmacy
  • Hospital Pharmacy
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Compounding Pharmacy Market 

5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area

8.1. Compounding Pharmacy Market, by Therapeutic Area, 2023-2032

8.1.1. Pain Management

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Hormone Replacement

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Dermal Disorders

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Nutritional Supplements

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Compounding Pharmacy Market, By Route of Administration

9.1. Compounding Pharmacy Market, by Route of Administration, 2023-2032

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Parenteral

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Compounding Pharmacy Market, By Application

10.1. Compounding Pharmacy Market, by Application, 2023-2032

10.1.1. Pediatric

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Geriatric

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Adult

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Veterinary

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Compounding Pharmacy Market, By Compounding Type

11.1. Compounding Pharmacy Market, by Compounding Type, 2023-2032

11.1.1. Pharmaceutical Dosage Alteration (PDA)

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Pharmaceutical Ingredient Alteration (PIA)

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Compounding Pharmacy Market, By Sterility

12.1. Compounding Pharmacy Market, by Sterility, 2023-2032

12.1.1. Sterile

12.1.1.1. Market Revenue and Forecast (2020-2032)

12.1.2. Non-sterile

12.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel

13.1. Compounding Pharmacy Market, by Distribution Channel, 2023-2032

13.1.1. Compounding Pharmacy

13.1.1.1. Market Revenue and Forecast (2020-2032)

13.1.2. Hospital Pharmacy

13.1.2.1. Market Revenue and Forecast (2020-2032)

13.1.3. Others

13.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.1.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.1.9.3. Market Revenue and Forecast, by Application (2020-2032)

14.1.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.1.10. Market Revenue and Forecast, by Sterility (2020-2032)

14.1.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.8.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.9. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.10. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.11.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.11.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.12. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.13. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.14. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.15.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.15.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.15.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.16. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.2.17.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.2.17.3. Market Revenue and Forecast, by Application (2020-2032)

14.2.17.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.2.18. Market Revenue and Forecast, by Sterility (2020-2032)

14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.10.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.11. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.12.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.12.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.12.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.12.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.3.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.3.13.3. Market Revenue and Forecast, by Application (2020-2032)

14.3.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.3.13.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.10.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.11. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.12. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.13.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.13.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.4.14.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.4.14.3. Market Revenue and Forecast, by Application (2020-2032)

14.4.14.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.4.14.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.7.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.8. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

14.5.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)

14.5.9.3. Market Revenue and Forecast, by Application (2020-2032)

14.5.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)

14.5.9.5. Market Revenue and Forecast, by Sterility (2020-2032)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 15. Company Profiles

15.1. Fresenius Kabi

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Fagron NV

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. B. Braun Medical Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Rx3 Compounding Pharmacy

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Clinigen Group PLC

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Dougherty’s Pharmacy, Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Lorraine’s Pharmacy

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Wedgewood Pharmacy

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Institutional Pharmacy Solutions

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Mcguff compounding pharmacy services

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Show More

Related Articles

Back to top button